Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment

Conditions

• Localized Anal Carcinoma
• Localized Anal Margin Carcinoma
• Stage 0 Anal Cancer AJCC v8
• Stage I Anal Cancer AJCC v8
• Stage II Anal Cancer AJCC v8
• Stage IIIB Anal Cancer AJCC v8

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Electronic Health Record Review — OTHER
  Ancillary studies
• Fluoroscopy — PROCEDURE
  Undergo fluoroscopy
• Ganglion Impar Neurolysis — PROCEDURE
  Undergo ganglion impar neurolysis
• Questionnaire Administration — OTHER
  Ancillary studies

Study Details

This clinical trial studies how well ganglion impar neurolysis works to improve radiation-induced pain during the treatment of anal or perianal skin cancer that has not spread to other parts of the body (localized). Treatment for anal or perianal skin cancer includes giving chemotherapy and radiation therapy (CRT) at the same time. CRT is frequently associated with several side effects, including radiation-induced pain. Despite advances in radiation therapy delivery, patients may still experience side effects which can lead to treatment breaks or treatment discontinuation. Ganglion impar neurolysis is a type of nerve block procedure in which medicine is injected directly into or around a nerve to block pain. The location of the procedure is near the tail bone and the medicine numbs the nerves that are in charge of sensation in the skin by the buttocks and genitalia. This may improve radiation-induced pain in patients receiving CRT for localized anal or perianal skin cancer.

Key Dates

Start date

Nov 10, 2025

Status verified

Jan 2026

Primary completion

Sep 30, 2026

Completion

Sep 30, 2027

Study Design

Enrollment

5 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Arms

• Experimental: Supportive care (ganglion impar neurolysis)
  Patients undergo ganglion impar neurolysis with fluoroscopy during week 4 of CRT on study.

Primary Outcome Measure

Frequency of treatment breaks [ Time Frame: Up to 6 weeks ]

Central Contacts

• Jolinta Y. Lin, MD
  404-778-1900
  [email protected]
• Vinita Singh, MD, MS
  404-778-1900
  [email protected]

Locations (2)

Find similar trials in Atlanta, GA